









Markets
/
Stocks
/
nasdaq-eq
/

Equillium Inc

1.520USD

+0.040+2.70%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

92.23MMarket Cap

LossP/E TTM



Equillium Inc

1.520

+0.040+2.70%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Equillium Inc

Currency: USD Updated: 2026-02-06

Key Insights

Equillium Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Equillium Inc's Score

Industry at a Glance

Industry Ranking

85 / 392

Overall Ranking

211 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Equillium Inc Highlights

StrengthsRisks

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 160.77% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.09M.

Fairly Valued

The company’s latest PE is -2.66, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 614.92K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 10.51.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.500

Target Price

+68.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Equillium Inc is 7.40, ranking 114 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 60328.57%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Equillium Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Equillium Inc is 6.92, ranking 201 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.66, which is -88.60% below the recent high of -0.30 and -297.84% above the recent low of -10.58.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Equillium Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 2.50, with a high of 4.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

2.500

Target Price

+68.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Equillium Inc

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Equillium Inc is 9.33, ranking 16 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.73 and the support level at 1.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.30

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.056

Buy

RSI(14)

62.917

Neutral

STOCH(KDJ)(9,3,3)

81.377

Neutral

ATR(14)

0.111

High Vlolatility

CCI(14)

101.990

Buy

Williams %R

16.914

Overbought

TRIX(12,20)

0.704

Sell

StochRSI(14)

84.123

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.506

Buy

MA10

1.425

Buy

MA20

1.285

Buy

MA50

1.227

Buy

MA100

1.267

Buy

MA200

0.980

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Equillium Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.39%, representing a quarter-over-quarter decrease of 11.86%. The largest institutional shareholder is The Vanguard, holding a total of 1.92M shares, representing 3.15% of shares outstanding, with 33.39% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Adar1 Capital Management LLC

5.56M

Adage Capital Management, L.P.

5.33M

Decheng Capital LLC

4.45M

Steel (Bruce D)

3.71M

Bradbury (Daniel M)

3.71M

Woodline Partners LP

3.51M

abrdn Inc.

379.53K

Biocon SA

2.32M

Balyasny Asset Management LP

2.00M

The Vanguard Group, Inc.

Star Investors

1.31M

+59.44%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Equillium Inc is 1.59, ranking 301 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.